Influence of mirtazapine on urinary free cortisol excretion in depressed patients

Psychiatry Research

Volumn 120, Issue 3, 2003, Pages 257-264

  Schule, Cornelius ^a   Baghai, Thomas ^a   Rackwitz, Constanze ^a   Laakmann, Gregor ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depressive disorder; HPA axis; Mirtazapine; Urinary free cortisol

Indexed keywords

HYDROCORTISONE; MIRTAZAPINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; HAMILTON SCALE; HUMAN; HYDROCORTISONE URINE LEVEL; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIANSERIN; MIDDLE AGED; PERSONALITY INVENTORY; SEX FACTORS; TREATMENT OUTCOME;

EID: 1642394045     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(03)00204-X     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;American Psychiatric Press, Washington, DC.
2. Asnis G.M., Halbreich U., Rabinovich H., Ryan N.D., Sachar E.J., Nelson B., Puig-Antich J., Novacenko H. The cortisol response to desipramine in endogenous depressives and normal controls: preliminary findings. Psychiatry Research. 14:1985;225-233.
3. Asnis G.M., Wetzler S., Sanderson W.C., Kahn R.S., van Praag H.M. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression and normal control subjects. Psychiatry Research. 43:1992a;65-76.
4. Asnis G.M., Sanderson W.C., van Praag H.M. Cortisol response to intramuscular desipramine in patients with major depression and normal control subjects: a replication study. Psychiatry Research. 44:1992b;237-250.
5. Barden N., Reul J.M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neuroscience. 18:1995;6-11.
6. Bech P., Gram L.F., Dein E., Jacobsen O., Vitger J., Bolwig T.G. Quantitative rating of depressive status. Acta Psychiatrica Scandinavica. 51:1975;161-170.
7. Daffner C., Laakmann G., Voderholzer U., Haag C., Baghai T., Kolmsee S., Schröder U., Munz T. The neuroendocrine effects of venlafaxine in healthy subjects. Human Psychopharmacology. 11:1996;1-9.
8. De Boer T.H., Maura G., Raiteri M., de Vos C.J., Wieringa J., Pinder R.M. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 27:1988;399-408.
9. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. International Clinical Psychopharmacology. 10:(Suppl. 4):1995a;19-23.
10. De Boer T., Ruigt G.S.F., Berendsen H.H.G. The alpha 2 selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology. 10:(Suppl. 2):1995b;107-119.
11. De Boer T.H., Nefkens F., Van Helvoirt A., van Delft A.M. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists mirtazapine, mianserin and idazoxan. Journal of Pharmacology and Experimental Therapeutics. 277:1996;852-860.
12. Haddjeri N., Blier P., de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. Journal of Pharmacology and Experimental Therapeutics. 277:1996;861-871.
13. Haddjeri N., Blier P., de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg's Archives of Pharmacology. 355:1997;20-29.
14. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 23:1960;56-62.
15. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Yassouridis A., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. American Journal of Psychiatry. 153:1996;93-99.
16. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
17. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in Neuropsychopharmacology and Biological Psychiatry. 6:1982;277-295.
18. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology. 9:(Suppl. 1):1994;S19-S26.
19. Kling M.A., Geracioti T.D., Licinio J., Michelson D., Oldfield E.H., Gold P.W. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. Psychopharmacology Bulletin. 30:1994;489-494.
20. Koizumi K., Aono T., Tanazawa O. The acute effects of antidepressants, maprotiline and amoxapine on serum prolactin and gonadotropin levels in normal woman. Asia Oceania Journal of Obstetrics and Gynaecology. 12:1986;517-521.
21. Laakmann G. Psychopharmaco-endocrinology and depression research. Monografias Gesamtgeb Psychiatric Psychiatry Series. 46:1988;1-220.
22. Laakmann G., Schule C., Baghai T., Waldvogel E. Effects of mirtazapine on growth hormone, prolactin and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 24:1999;769-784.
23. Murphy B.E. Steroids and depression. Journal of Steroid Biochemistry and Molecular Biology. 38:1991;537-559.
24. Nutt D., Middleton H., Franklin M. The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology. 12:1987;367-375.
25. Pasquali R., Ambrosi B., Armanini D., Cavagnini F., Uberti E.D., Del Rio G., de Pergola G., Maccario M., Mantero F., Marugo M., Rotella C.M., Vettor R. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution and dexamethasone concentrations: a dose-response study. Journal of Clinical Endocrinology and Metabolism. 87:2002;166-175.
26. Petraglia F., Facchinetti F., Martignoni E., Nappi G., Volpe A., Genazzani A.R. Serotonergic agonists increase plasma levels of beta-endorphin and beta-lipotropin in humans. Journal of Clinical Endocrinology and Metabolism. 59:1984;1138-1142.
27. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatric Clinics of North America. 21:1998;293-307.
28. Rubin R.T., Rhodes M.E., O'Toole S., Czambel R.K. Sexual iergism of hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine in elderly vs. young women and men. Neuropsychopharmacology. 26:2002;672-681.
29. Sawa Y., Odo S., Nakazawa T. Growth hormone secretion by tricyclic and non-tricyclic antidepressants in healthy volunteers and depressives. Advances in Bioscience. 40:1982;309-315.
30. Schule C., Baghai T., Goy J., Bidlingmaier M., Strasburger C., Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology. 163:2002a;95-101.
31. Schule C., Baghai T., Bidlingmaier M., Strasburger C., Laakmann G. Endocrinological effects of mirtazapine in healthy volunteers. Progress in Neuropsychopharmacology and Biological Psychiatry. 26:2002b;1253-1261.
32. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology. 14:1996;253-363.
33. Skene D.J., Bojkowski C.J., Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. British Journal of Clinical Pharmacology. 37:1994;181-186.
34. Stokes P.E., Stoll P.M., Koslow S.H., Maas J.W., Davis J.M., Swann A.C., Robins E. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. Archives of General Psychiatry. 41:1984;257-267.
35. Timmer C.J., Paanakker J.E., Vrijmoed-de Vries M. Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Pharmaceutical Research. 14:1997;98-102.
36. Von Bardeleben U., Steiger A., Gerken A., Holsboer F. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. International Clinical Psychopharmacology. 4:(Suppl. 1):1989;1-5.
37. World Medical Association, 2000. World Medical Association Declaration of Helsinki, ethical principles for medical research involving human subjects. Ferney-Voltaire', WMA, 2000. http, //www.wma.net/e/policy/17-c_e.html.
38. Young E.A. Sex differences and the HPA axis: implications for psychiatric disease. Journal of Gender Specific Medicine. 1:1998;21-27.
39. Zivkov M., Roes K.C.B., Pols A.G. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder, a meta-analysis. Human Psychopharmacology. 10:(suppl.2):1995;135-145.